Literature DB >> 15305945

Exhaled NO and eosinophil markers in blood, nasal lavage and sputum in children with asthma after withdrawal of budesonide.

Karin Lönnkvist1, Martin Anderson, Gunilla Hedlin, Magnus Svartengren.   

Abstract

BACKGROUND: There is a need for controlled trials among children with asthma to evaluate and compare different markers of inflammation.
OBJECTIVE: Our goal was to investigate the effect of withdrawal of inhaled budesonide on repeated measurements of exhaled NO (ENO), peripheral blood eosinophils (PBE), sputum/NAL/serum-eosinophil cationic protein (ECP), bronchial hyperresponsiveness (BHR) and forced expiratory volume in 1 s (FEV(1)) in children with allergic asthma.
METHODS: Eighteen asthmatic children were randomly allocated to continue or discontinue use of inhaled budesonide. They were followed up, at six visits for 4 months with regular blood, serum, sputum, and NAL samples. Sixteen age-matched healthy children served as controls.
RESULTS: ENO, PBE, and S-ECP increased significantly in the withdrawal group (p < 0.05) but not in the continuous treatment group. No trend could be observed during the study for markers in sputum or in NAL in either group.
CONCLUSION: The present data provide evidence for the clinical usefulness of measuring ENO, PBE, and S-ECP and when combined they could help to avoid over- and undertreatment with corticosteroids in the growing child.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15305945     DOI: 10.1111/j.1399-3038.2004.00165.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  3 in total

1.  Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children.

Authors:  Sheel N Shah; Jocelyn R Grunwell; Ahmad F Mohammad; Susan T Stephenson; Gerald B Lee; Brian P Vickery; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-27

2.  Salivary inflammatory mediator profiling and correlation to clinical disease markers in asthma.

Authors:  Frédéric F Little; Diana M Delgado; Philip J Wexler; Frank G Oppenheim; Patricia Mitchell; James A Feldman; David R Walt; Roger D Peng; Elizabeth C Matsui
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

3.  A Pilot Randomized Trial of As-Needed Budesonide-Formoterol for Stepping Down Controller Treatment in Moderate Asthma with Complete Remission.

Authors:  Narongwit Nakwan; Thidarat Ruklerd; Pattarawadee Taptawee
Journal:  Tuberc Respir Dis (Seoul)       Date:  2022-05-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.